The delineated upregulation of key NO-generating isoforms of liver NO synthase and an increase in the total activity of NOS are probably aimed at compensating for the reduced bioavailability of nitrogen oxide in diabetes and more effectively accomplishing its physiological functions in hepatocellular signaling. The gene discussed is NOS2; the disease is diabetes mellitus.